Oral Insulin Composition With Omega-3 Protection and Absorption

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for administering insulin, a key treatment for diabetes, involve daily injections, which cause discomfort and do not mimic the natural regulation of insulin secretion, and oral administration of peptides is ineffective due to low absorption.

Innovation Solution

A composition comprising insulin and omega-3 fatty acids is developed for oral administration, enhanced by protease inhibitors and absorption enhancers, allowing insulin to maintain enzymatic activity and absorption through the intestinal mucosal barrier.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If insulin is administered via injection, then the therapeutic effect is achieved, but patient compliance deteriorates and side effects increase

Engineering Contradiction:
Improvetherapeutic effectVSAvoidpatient compliance
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces the mechanical injection system with an oral delivery system. Insulin is administered through the gastrointestinal tract using a capsule or tablet formulation, eliminating needles and injection-related discomfort while maintaining therapeutic efficacy through intestinal absorption.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the physical and chemical parameters of insulin to enable oral delivery. This includes modifying the formulation to protect insulin from degradation in the GI tract, using absorption enhancers to increase intestinal permeability, and controlling release characteristics to ensure adequate absorption while maintaining compliance.

Inventive Principle:
Principle #35Parameter changes

2Ease of operation

If insulin is administered orally without protection, then ease of administration improves, but enzymatic degradation increases

Engineering Contradiction:
Improveease of administrationVSAvoidenzymatic activity
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent applies preliminary protective actions to insulin before oral administration. The insulin is encapsulated in a protective matrix or coated with materials that shield it from gastrointestinal enzymes and acidic conditions, ensuring it reaches the absorption site intact and maintains its enzymatic activity.

Inventive Principle:
Principle #10Preliminary action

3Quantity of substance

If oral absorption of insulin is enhanced, then bioavailability improves, but intestinal barrier penetration becomes more difficult

Engineering Contradiction:
ImprovebioavailabilityVSAvoidintestinal barrier penetration
Core Design Contradiction:
Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent uses intermediary substances to facilitate insulin's passage through the intestinal barrier. These include absorption enhancers, permeation promoters, or carrier molecules that temporarily interact with insulin to help it cross the intestinal epithelium, then release it into the bloodstream, thereby improving bioavailability without requiring complex delivery devices.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables effective oral delivery of insulin with sustained activity, reducing injection frequency and minimizing side effects, providing continuous metabolic regulation.

Implementation Method 1

enhanced by protease inhibitors and absorption enhancers, allowing insulin to maintain enzymatic activity

Methodology Applied
Scientific EffectProtease inhibition:

Implementation Method 2

allowing insulin to maintain enzymatic activity and absorption through the intestinal mucosal barrier

Methodology Applied
Scientific EffectAbsorption enhancement: Absorption (physical)

Data Source

PatentUS20250281579A1Methods and Compositions for Oral Administration of Proteins
Publication Date: 2025.09.11 ORAMED PHARMA INC

AI summary

This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.